Increased food intake is characteristic of hyperthyroidism, although this is presumed to compensate for a state of negative energy balance. However, here we show that the thyroid hormone T 3 directly stimulates feeding at the level of the hypothalamus. Peripheral administration of T 3 doubled food intake in ad libitum-fed rats over 2 h and induced expression of the immediate early gene, early growth response-1, in the hypothalamic ventromedial nucleus (VMN), whereas maintaining plasma-free T 3 levels within the normal range. T 3 -induced feeding occurred without altering energy expenditure or locomotion. Injection of T 3 directly into the VMN produced a 4-fold increase in food intake in the first hour. The majority of T 3 in the brain is reported to be produced by tissue-specific conversion of T 4 to T 3 by the enzyme type 2 iodothyronine deiodinase (D2). Hypothalamic D2 mRNA expression showed a diurnal variation, with a peak in the nocturnal feeding phase. Hypothalamic D2 mRNA levels also increased after a 12-and 24-h fast, suggesting that local production of T 3 may play a role in this T 3 feeding circuit. Thus, we propose a novel hypothalamic feeding circuit in which T 3 , from the peripheral circulation or produced by local conversion, stimulates food intake via the VMN. (Endocrinology 145: 5252-5258, 2004) I N HYPERTHYROIDISM, ELEVATED PLASMA levels of thyroid hormones increase energy expenditure and decrease body weight (1). It is widely assumed that the characteristic increased appetite of hyperthyroidism is compensatory for this state of negative energy balance. Interestingly, about 5-10% of hyperthyroid individuals have a sufficiently increased appetite to gain weight despite the catabolic thyrotoxic process (2), suggesting that thyroid hormones may directly stimulate feeding.
I
N HYPERTHYROIDISM, ELEVATED PLASMA levels of thyroid hormones increase energy expenditure and decrease body weight (1) . It is widely assumed that the characteristic increased appetite of hyperthyroidism is compensatory for this state of negative energy balance. Interestingly, about 5-10% of hyperthyroid individuals have a sufficiently increased appetite to gain weight despite the catabolic thyrotoxic process (2) , suggesting that thyroid hormones may directly stimulate feeding.
T 3 is the biologically active thyroid hormone. Tissue T 3 concentrations are controlled at the cellular level and may not reflect plasma thyroid hormone concentrations (3) . Thus, within the rat central nervous system (CNS), physiological levels of T 3 are largely dependent on cellular uptake and intracellular deiodination of T 4 to T 3 by type 2 iodothyronine deiodinase (D2) (4, 5) . Within the hypothalamus, D2 mRNA (6, 7) and activity (8) are concentrated in the periventricular region of the third ventricle, the arcuate nucleus (ARC) and median eminence. D2 mRNA is localized to tanycytes, specialized ependymal cells lining the third ventricle (9) . Tanycytes have long cytoplasmic processes projecting to several hypothalamic nuclei, including the ARC and the ventromedial nucleus (VMN) (10) . The function of this local hypothalamic T 3 production is unknown.
The hypothalamus plays an essential role in the regulation of energy homeostasis, integrating signals from other areas of the CNS and the periphery. Several hypothalamic nuclei have been implicated in the regulation of food intake and energy balance including the ARC, paraventricular nucleus (PVN), and VMN. Within the ARC two important neuronal populations have been identified: appetite inhibiting proopiomelanocortin (POMC)-expressing neurons and appetite-stimulating neuropeptide Y (NPY) and agouti-related protein (AgRP)-coexpressing neurons (11) . Both of these neuronal populations project to the PVN. The VMN was labeled as a satiety center more than 50 yr ago when studies demonstrated that lesioning the VMN resulted in hyperphagia and weight gain (12) . However, more recent studies suggest that the role of the VMN in appetite regulation is more complex. The VMN receives and sends out extensive projections to other regions of the hypothalamus including the PVN and dorsomedial hypothalamus and may modulate the release of orexigenic signals from these hypothalamic nuclei (13) .
The effects of overt hyperthyroidism and hypothyroidism on energy homeostasis and appetite have been well established in rodents and man (14 -16) . However, such states are associated with marked effects on behavior and metabolism. Therefore, it is not possible to infer from these studies a physiological role for thyroid hormones in the regulation of food intake. To investigate a role for T 3 in the physiological regulation of food intake, we studied the effects of peripheral and CNS administration of T 3 , using doses of T 3 that did not elevate plasma free T 3 (fT3) levels outside the normal range (referred to as low-dose T 3 for the remainder of the paper). We examined the effects of low-dose T 3 on food intake, energy expenditure, and behavior. In addition, we studied diurnal variation and the effect of short-term fasting on hypothalamic D2 mRNA expression.
Materials and Methods

Animal care and maintenance
Male Wistar rats (ICSM, London, UK) (200 -250 g) aged 7-8 wk were maintained under standardized barrier conditions (21-23 C, lights on 0700 -1900 h) and fed ad libitum RM1 diet (SDS Ltd., Witham, UK) unless described otherwise. All animal procedures were conducted under the British Home Office Animals (Scientific Procedures) Act (1986). All injections were administered in the early light phase (0700 -0900 h).
T 3 preparation for peripheral administration
For peripheral (sc) injections, T 3 was prepared as T 3 (Sigma, Dorset, UK) dissolved in absolute ethanol and emulsified in safflower oil (1:10) (volume 0.1 ml). Controls received vehicle (emulsion alone). Before all studies, animals received two sham sc saline injections.
Peripheral administration of T 3 and food intake
In the acute study of the effects of T 3 on food intake, animals received either sc T 3 (1.1, 2.3, or 4.5 nmol/kg) or sc vehicle (n ϭ 12 per group). Food was weighed at 2, 4, 8, and 24 h post injection. In a separate study, animals received sc T 3 (4.5 nmol/kg) or vehicle (controls) and were killed 2 h post injection by decapitation for collection of trunk blood as described (17) . In the chronic study, animals (n ϭ 12 per group) were injected with sc T 3 (4.5, 9, or 75 nmol/kg) or sc vehicle daily for 5 d. On d 5 trunk blood was collected. Brains were removed and hypothalami dissected out and snap frozen for subsequent measurement of neuropeptide mRNA expression by RNase protection assay (RPA) (described below). Interscapular brown adipose tissue (BAT) and epididymal white adipose tissue were also collected and then weighed and frozen. BAT uncoupling protein 1 (UCP-1) mRNA expression was measured by RPA.
RIA
Plasma TSH levels were assayed using methods and reagents (kindly provided by A. Parlow, National Institute of Diabetes and Digestive and Kidney Diseases, National Hormone and Pituitary Program, Torrance, CA) as previously described (17) . Plasma leptin (Linco Research, St. Charles, MO), fT3 and free T 4 (fT4) (Diagnostic Products Corp., Los Angeles, CA) were measured using commercial RIAs following the manufacturer's instructions.
Behavioral study
Animals received a sc injection of T 3 (4.5 nmol/kg) or vehicle at time 0 (n ϭ 16 per group). Behavioral patterns were monitored continuously from 30 to 120 min by observers blinded to the experimental treatment. Behavior was classified into three different categories [adapted from Abbott et al. (18) ]: feeding; active nonfeeding behavior (drinking, grooming, burrowing, rearing, locomotion); and inactive nonfeeding behavior (sleeping and still). These methods have previously been used to demonstrate abnormal behaviors after CNS administration of peptides (18) . During the analysis, each rat was observed for 12 sec every 5 min. This 12-sec period was subdivided into three and the behavior of the rat during each section of the time period scored (816 total observations per rat).
Oxygen consumption (VO 2 ) studies
Indirect calorimetry was used to measure VO 2 as an indirect measurement of energy expenditure as previously described (19) . VO 2 was determined in closed circuit respirometers maintained at thermoneutral temperature for rats (29 C). Animals were acclimatized to the calorimetry chamber for 2 h before injection (n ϭ 8 per group) and injected with T 3 or vehicle at time 0. VO 2 was measured for 240 min after treatment. To study the acute effects of T 3 on VO 2 , calorimetry was performed after a single sc injection of 4.5 nmol/kg T 3 or vehicle. This was repeated after a single ip injection of the ␤ 3 -adrenoceptor agonist BRL 35135 (40 g/kg) as a positive control (20) . To study the effects of chronic T 3 administration on VO 2 , animals received 5 d of once-daily sc injections of T 3 (4.5 or 75 nmol/kg) or vehicle, and calorimetry was performed on d 5.
RPA
Total RNA was extracted from hypothalami and BAT collected from animals after a single sc T 3 injection or 5 d of once-daily T 3 injections (4.5 nmol/kg) (n ϭ 12 per group) using Tri-Reagent (Helena Biosciences, Sunderland, UK) following the manufacturer's protocol. Hypothalamic AgRP, POMC, NPY, and D2 (all 5 g) and BAT UCP-1 (0.25 g) mRNA were quantified by RPA (21) (RPA III kit, Ambion Inc., Austin, TX) using in-house probes (accession no.: UCP-1 M11814, AgRP U89484, POMC NM_139326, NPY NM_012614, and D2 NM_031720). Rat ␤-actin was used as an internal control (Ambion). RNA was hybridized overnight and separated on a 5% polyacrylamide gel. The dried gel was exposed to a PhosphorImager screen overnight and protected RNA hybrids quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, CA). For each neuropeptide, the ratio of the OD of the band of neuropeptide mRNA to that of ␤-actin was calculated and expressed in relative units (RU) (22) .
Immunocytochemistry (ICC)
Early growth response (Egr)-1 immunoreactivity (IR) was measured by ICC in paraffin-embedded, paraformaldehyde-fixed male Wistar rat brains collected 2 h after sc administration 4.5 nmol/kg T 3 or vehicle (23) . Nonspecific binding was blocked using normal donkey serum and sections incubated in rabbit anti Egr-1 antibody (Santa Cruz Biotechnology, Santa-Cruz, CA) diluted 1:1000 at 4 C overnight. Slides were incubated for 30 min in biotinylated donkey antirabbit secondary antibody (1:50) (Jackson ImmunoResearch Laboratories Inc., West Grove, PA) followed by a 30-min incubation in ABC-horseradish peroxidase (1:100) (Dako Cytomation, Glostrup, Denmark). The antigen-antibody complex was visualized with 3,3Ј-diaminobenzidine in 0.01% hydrogen peroxide. Every fifth section was stained with hematoxylin and eosin to allow identification of the relevant hypothalamic nuclei. Egr-1-IR was counted by an observer blinded to the experimental treatment using an Eclipse E800 microscope (Nikon, Tokyo, Japan) and Image Pro-Plus software (version 4.5, MediaCybernetics, Silver Spring, MD).
Intranuclear cannulation and injection of T 3
Animal surgical procedures and handling were carried out as previously described (18) . Animals were anesthetized by ip injection of a mixture of Ketalar (ketamine HCl 60 mg/kg; Parke-Davis, Pontypool, UK) and Rompun (xylazine 12 mg/kg; Bayer UK Ltd., Bury St. Edmonds, UK) and placed on a stereotaxic frame (David Kopf Instruments, Tujunga, CA). Permanent 26-gauge stainless steel guide cannulae (Plastics One Inc., Roanoke, VA) were stereotactically placed into the hypothalamic VMN or ARC as previously described (24) . Due to its low solubility, T 3 was dissolved in 5% ethanol. We have previously shown that CNS injection of up to 70% ethanol does not produce behavioral abnormalities (25) . Animals received 0.5, 1, 5, and 50 pmol T 3 or vehicle administered in 1 l. Food was weighed at 1, 2, 4, 8, and 24 h post injection. Cannula placement was verified at the end of the study by the injection of black ink (26). Data from an animal were excluded if its injection site extended more than 0.2 mm outside the intended hypo-thalamic injection site or if any ink was detected in the cerebral ventricular system.
Measurement of D2 mRNA expression
For the fasting study, hypothalami were dissected and collected from rats either fed ad libitum (control) or fasted for 12 or 24 h (n ϭ 10 per group). For the diurnal variation study, rats were killed at nine time points (n ϭ 10 per group) throughout a 24-h period. Hypothalamic D2 mRNA levels were measured using RPA (as described).
Statistical analysis
Statistical analyses were carried out in collaboration with David Stephens (Department of Mathematics, Imperial College, London, UK). Values are presented as the mean Ϯ sem unless otherwise stated. Behavioral data are presented as percent of total observations Ϯ estimated se. A Bayesian analysis was used to compare the relative probabilities of each behavioral profile in each group. For VO 2 studies, groups of data were compared using a two-way analysis of covariance (S-plus, Seattle, WA). For Egr-1 studies (data expressed as median values with interquartile ranges), a Wilcoxon nonparametric test was used. In the remaining studies, comparisons were made using ANOVA, with post hoc Fisher's least significant difference method (Systat, Evanston, IL). Normal ranges (mean Ϯ 2 sd) for thyroid hormones were calculated within our laboratory from euthyroid control rats. Polynomial regression analysis was used for studying D2 mRNA diurnal rhythm (version 2.03, SigmaStat, Chicago, IL). P Ͻ 0.05 was considered significant.
Results
Acute effects of peripheral T 3 on food intake, plasma hormones, and behavior
Two hours post sc injection of T 3 (4.5 nmol/kg), food intake increased by 140% [1.2 Ϯ 0.3 (T 3 ) vs. 0.5 Ϯ 0.1 g (control), P Ͻ 0.05] (Fig. 1A) . This stimulatory effect persisted for 8 h [5-8 h: 1.3 Ϯ 0.4 (T 3 ) vs. 0.6 Ϯ 0.1 g (control), P Ͻ 0.05] (Fig. 1B) . Lower doses of T 3 had no effect on feeding. Twentyfour hours post injection, there was no difference in food intake between T 3 -treated and control animals.
Plasma leptin levels were unchanged 2 h after T 3 treatment (4.5 nmol/kg) [ (Fig. 2 A) . the dose 4.5 nmol/kg T 3 also significantly increased cumulative food intake [d 0 -5: 116.0 Ϯ 1.7 (T 3 ) vs. 107.6 Ϯ 1.9 g (control), P Ͻ 0.05] (Fig. 2B) . The highest dose of T 3 , 75 nmol/kg, did not increase feeding. Consistent with the increased food intake, cumulative weight gain was 30% greater in the 4.5 nmol/kg T 3 group, although this did not reach statistical significance [d 5: 23.3 Ϯ 1.6 (T 3 ) vs. 18.2 Ϯ 2.1 g (control), P ϭ 0.1] (Fig. 2C) .
The effects of chronic administration of T 3 on body adiposity, plasma leptin, and thyroid hormones are shown in Table 1 . Chronic treatment with 4.5 nmol/kg T 3 also increased plasma fT3 by 40%, although this remained within the normal range. Plasma TSH was lowered by 20% (P Ͻ 0.05), compared with controls, but again remained within the normal range. Although 9 nmol/kg T 3 had some stimulatory effects on feeding, this was associated with suppression of the thyroid axis ( Table 1 
Effects of acute and chronic peripheral administration of T 3 on energy expenditure
After a single injection of T 3 (4.5 nmol/kg), VO 2 was unchanged compared with control animals (Fig. 3A) . However, an ip injection of the ␤ 3 -adrenoreceptor agonist BRL 35135 significantly increased VO 2 as previously reported (20) (Fig.  3B) . Similarly, once-daily injection of 4.5 nmol/kg T 3 for 5 d did not alter d 5 VO 2 (Fig. 3C) . After chronic daily administration of 75 nmol/kg T 3 , basal VO 2 had significantly in- (Fig. 3D ). This elevation in VO 2 remained evident for the duration of VO 2 measurement (240 min).
Effects of acute and chronic peripheral T 3 treatment on hypothalamic neuropeptide mRNA expression
After a single injection of T 3 (4.5 nmol/kg), hypothalamic POMC mRNA, AgRP mRNA, and NPY mRNA levels were unchanged, compared with control animals (data not shown). This was also true of 5 d of daily administration of T 3 (4.5, 9, 75 nmol/kg) ( Table 1) .
Determination of neuronal activation after peripheral T 3 injection
Within the CNS, T 3 induces expression of the Egr family of transcription factors (27, 28) yet may inhibit c-fos expression (29, 30). Therefore, to investigate a potential hypothalamic site of action for peripheral T 3 , Egr-1-IR was examined. Peripheral T 3 injection was associated with a significant increase in the number of cells positive for Egr-1 in the VMN [median value (interquartile range): 1080 (879:1282) (T 3 ) vs. 642 (620:664) immunoreactive cells (control), P Ͻ 0.05 (Fig. 4,  A and B 
Effects of intranuclear administration of T 3 on food intake
In view of the findings from these ICC studies, we studied the effects of injection of T 3 (0.5, 1, 5, or 50 pmol) directly into the VMN. All doses of T 3 significantly increased food intake 1 h post injection (Fig. 4C) . Fifty picomoles T 3 produced a 4-fold stimulation in feeding [0 -1 h: 3.1 Ϯ 0.5 50 pmol (T 3 ) vs. 0.8 Ϯ 0.2 g (control), P Ͻ 0.0001]. This stimulatory effect on food intake was short lived. Food intake between 1-2 and 2-4 h post injection was unchanged, compared with controls. In contrast, intra-ARC injection of T 3 did not alter food intake at any dose (P ϭ 0.3).
Hypothalamic D2 mRNA expression
Effect of fasting
In animals fasted for 12 and 24 h, hypothalamic D2 mRNA expression was increased by approximately 50%, compared with fed controls [5.9 Ϯ 0.6 (12-h fast) vs. 4.0 Ϯ 0.5 RU (fed), P Ͻ 0.05, 6.1 Ϯ 0.9 (24-h fast) vs. 4.0 Ϯ 0.5 RU (fed), P Ͻ 0.05] (Fig. 5A) .
Diurnal variation
Hypothalamic D2 mRNA expression exhibited a diurnal rhythm (Fig. 5B) , reaching a nadir at 1500 h, 8 h after lights on. Subsequently, D2 mRNA expression progressively increased, with maximal levels at 2300 h, 4 h after lights out. This peak D2 mRNA expression was significantly greater than all other light-phase time points (P Ͻ 0.05). A 3-fold change in D2 mRNA expression was observed through the 24-h period. Trend analysis by polynomial fit revealed a cubic relationship between D2 mRNA expression and time of day (P ϭ 0.001).
Discussion
We have demonstrated a novel role for T 3 in the stimulation of food intake. This effect was seen using T 3 doses substantially lower than those used by other groups (14, 31) . In our study, plasma fT3 levels were increased by approximately 40% but remained within the normal range after acute and chronic peripheral administration of 4.5 nmol/kg T 3 . In contrast, the higher doses of T 3 produced up to a 5-fold increase in plasma fT3 and were associated with a marked suppression of plasma fT4 and TSH. Supraphysiological levels of T 3 are likely to result in metabolic and behavioral changes that would make the effects on food intake difficult to interpret. Therefore, in our experiments studying the effects of low-dose T 3 on feeding, we were careful to adjust the dose of T 3 to maintain fT3 levels within the normal range. In our studies, we peripherally administered T 3 , the biologically active thyroid hormone, which readily crosses the blood-brain barrier (32, 33). Our results support a direct effect of T 3 on feeding because this stimulation occurred in the absence of changes in energy expenditure, behavior, or plasma leptin. The chronic orexigenic effect of T 3 is unlikely to be a compensatory response to weight loss because our data showed that the dose of T 3 that stimulated feeding (4.5 nmol/kg) was actually associated with a trend toward increased weight gain. The well-characterized effects of thyroid hormones are mediated by nuclear hormone receptors via activation of gene transcription and occur over a period of hours to days (34). However, a number of thyroid hormone effects occur more rapidly and are independent of the cell nucleus (34, 35). These nongenomic effects of thyroid hormones have been described in a variety of tissues (36 -39).
The rapid increase in feeding after T 3 injection observed in the current study suggests such a nongenomic effect. In rodents, BAT is the major site of adaptive thermogenesis due to the expression of uncoupling proteins. UCP-1 is exclusive to BAT, and thyroid hormones are permissive for UCP-1 expression (40). We found that peripheral administration of low-dose T 3 for 5 d increased food intake without any alteration in BAT weight or UCP-1 mRNA levels. This suggests that the orexigenic effect of T 3 is not secondary to changes in adaptive thermogenesis. Consistent with this, energy expenditure, measured as VO 2 , was unchanged after both acute and chronic peripheral administration of lowdose T 3 . Thyrotoxicosis is associated with a significant increase in physical activity, and this alteration in energy balance may contribute to the characteristic increased food intake. However, we found that administration of low-dose T 3 increased feeding behavior without altering locomotor activity.
Our studies demonstrate a role for the VMN in the feeding response to T 3 . Although early studies (12) demonstrated that lesioning of the VMN produces hyperphagia and obesity, more recent work (41, 42) suggests a more complex role for the VMN in appetite regulation. The VMN has projections to a number of hypothalamic nuclei involved in appetite regulation (43), and disruption of the VMN alters the expression of NPY mRNA in the ARC and NPY peptide in the PVN (44). However, it is unlikely that either the ARC or PVN is the primary site of action for the stimulatory feeding effects of T 3 because peripheral T 3 did not increase Egr-1-IR in either of these nuclei. In addition, injection of T 3 into the ARC, unlike the VMN, did not affect feeding. The observed increase in food intake produced by T 3 may not be mediated by well-characterized neuropeptide regulators of feeding, such as POMC, AgRP, or NPY, because their hypothalamic mRNA expression was unaltered after chronic T 3 administration. However, changes in peptide synthesis and release may occur in the absence of altered mRNA expression. Other molecules involved in the regulation of food intake, such as dopamine (45), serotonin (45), and brain-derived neurotrophic factor (46), are expressed in the VMN, and their expression is altered by nutritional status. Therefore, the possible involvement of such neuromodulators of feeding cannot be excluded.
Rats display a diurnal pattern in feeding, and many neuropeptides involved in the regulation of food intake show a similar diurnal pattern in expression, i.e. AgRP (47), NPY (48), and POMC (48). Campos-Barros et al. (49) have shown that in rats, hypothalamic T 3 concentrations peak just before the onset of the dark phase when feeding begins and hypothalamic D2 activity is maximal in the middark phase. Consistent with this we demonstrated a diurnal variation in hypothalamic D2 mRNA, with levels greatest 4 h into the dark phase. A previous study (6) has shown that hypothalamic D2 mRNA expression increases after a prolonged, 72-h fast. However, this duration of fasting was associated with pronounced suppression of the thyroid axis. We have shown that hypothalamic D2 mRNA expression is increased after only 12 h of fasting, which is more relevant to the daily regulation of food intake. This increase in hypothalamic D2 mRNA levels with fasting may increase hypothalamic T 3 levels and hence stimulate appetite. One way to investigate this would be to inhibit the action of D2, for example with reverse T 3 , and examine the effects of this inhibition on food intake.
Studies suggest that T 4 is taken up by tanycytes from the cerebrospinal fluid and capillaries and converted by D2 to the active hormone T 3 for use in various hypothalamic regions (50). Therefore, T 3 may be transported, possibly by tanycytes, to the VMN to stimulate food intake. These data have led us to propose a hypothalamic circuit involving T 3 , which is regulated by daily energy requirements. The source of T 3 may be the peripheral circulation or locally derived in the hypothalamus by deiodination of T 4 to T 3 by D2.
Previously the role of thyroid hormones in energy balance has been largely confined to pathological states, such as hyperthyroidism. The effects of thyroid hormones on appetite have been presumed to be secondary to increased metabolism. Here we propose a novel role for T 3 in the regulation of daily food intake via the hypothalamic VMN.
FIG. 5. Hypothalamic D2 mRNA increases with fasting and has a diurnal variation. A, Hypothalamic D2 mRNA expression in rats fasted for 12 and 24 h, compared with ad libitum-fed rat (n ϭ 10/ group). *, P Ͻ 0.05 vs. fed group. B, Hypothalamic D2 mRNA expression over a 24-h period (n ϭ 10/group). Black line denotes duration of dark phase. *, P Ͻ 0.05 vs. D2 mRNA expression at all other light phase time points. Results are mean Ϯ SEM.
